OverviewSuggest Edit

The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
TypePrivate
Founded2011
HQLondon, GB
Websitesynthace.com

Latest Updates

Employees (est.) (Sept 2020)80
Revenue (FY, 2013)£581
Cybersecurity ratingBMore

Key People/Management at Synthace

Bob Wiederhold

Bob Wiederhold

Chairman
Tim Fell

Tim Fell

Chief Executive Officer, Director
Christopher Grant Ward

Christopher Grant Ward

Co-Founder
Susan Shiff

Susan Shiff

Non-Executive Director
Isabel Fox

Isabel Fox

Non-Executive Director
Patrick Zhang

Patrick Zhang

Non-Executive Director
Show more

Synthace Office Locations

Synthace has offices in London and Cambridge
London, GB (HQ)
195 Wood Ln, Shepherd's Bush
Cambridge, US
101 Main St
Show all (2)

Synthace Financials and Metrics

Summary Metrics

Synthace's latest funding round in December 2018 was reported to be $25.6 m. In total, Synthace has raised $41.8 m
Show all financial metrics

Synthace Revenue

Synthace's revenue was reported to be £581 in FY, 2013
GBP

Revenue (FY, 2013)

581.0

Net income (FY, 2013)

(361.6k)

EBITDA (FY, 2013)

(356.8k)

EBIT (FY, 2013)

(361.6k)

Cash (31-May-2018)

4.9m
GBPFY, 2012FY, 2013

Revenue

581.0

Operating expense total

362.2k

EBITDA

(356.8k)

EBITDA margin, %

(61413%)
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

351.4k103.4k321.7k1.5m245.0k224.3k4.9m

Accounts Receivable

240.0159.9k73.2k9.6k46.6k107.7k

Current Assets

358.1k150.1k481.6k1.6m646.8k883.2k5.8m

PP&E

1.6k14.8k298.8k200.5k265.6k186.8k235.7k
GBPFY, 2012FY, 2013

Net Income

(43.1k)(361.6k)
GBPFY, 2012

Financial Leverage

1 x
Show all financial metrics

Synthace Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Synthace Online and Social Media Presence

Embed Graph

Synthace News and Updates

Synthace raises $25.6 million to automate bio labs with software

Synthace, a U.K. startup developing an operating system to automate lab work, announced that it has raised $25.6 million in a Series B round.

Synthace reels in $9.6 mln Series A

London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.

Synthace Blogs

Here’s Why You Should Stop Doing Science Like You Were Taught in High School: Part 3

 Check out Part 1 and Part 2 of “Here’s Why You Should Stop Doing Science Like You Were Taught in High School”. In this series of blog posts, we challenge the traditional one-factor-at-a-time (OFAT) approach to doing science, which most of us were taught in school and continue to use until now. This…

Building Equal and Inclusive Work Environments for Underrepresented Communities

 In the past few weeks, equality and inclusivity have been the trending topics on social media, with companies across the globe promoting diversity in their teams and expressing their support for underrepresented communities. Indeed, in light of the worldwide Black Lives Matter movement, plus June b…

People of Synthace: Adam Vartanian, Senior Software Engineer

The work I'm doing directly translates into new features in the product that we go out and try to sell to customers.

Here’s Why You Should Stop Doing Science Like You Were Taught in High School: Part 2

 Read “Here’s Why You Should Stop Doing Science Like You Were Taught in High School: Part 1” From One-Factor-At-A-Time to Design of Experiments One-factor-at-a-time (OFAT) methods were widely adopted by scientists to simplify the study of complex systems. One component (factor) is picked at a time a…

Advice for Scientists Returning to the Lab

 As lockdown restrictions begin to ease across the globe and people return to work, lab scientists will also be returning to their projects and trying to get them back on track as soon as possible. But what challenges or hurdles will scientists initially need to overcome on their return, and are the…

Computer-Aided Biology: The Metadata Responsibility

  New whitepaper by Synthace highlights the crucial role of metadata in an AI and automation powered lab of the futureLONDON June 17, 2020 - Synthace Ltd, the company behind Antha, the cloud-based software platform for automating and improving the success rate of biological processes, is pleas…
Show more

Synthace Frequently Asked Questions

  • When was Synthace founded?

    Synthace was founded in 2011.

  • Who are Synthace key executives?

    Synthace's key executives are Bob Wiederhold, Tim Fell and Christopher Grant Ward.

  • How many employees does Synthace have?

    Synthace has 80 employees.

  • What is Synthace revenue?

    Latest Synthace annual revenue is £581 .

  • What is Synthace revenue per employee?

    Latest Synthace revenue per employee is £7 .

  • Who are Synthace competitors?

    Competitors of Synthace include International Stem Cell Corporation, Transgene and Clementia Pharmaceuticals.

  • Where is Synthace headquarters?

    Synthace headquarters is located at 195 Wood Ln, Shepherd's Bush, London.

  • Where are Synthace offices?

    Synthace has offices in London and Cambridge.

  • How many offices does Synthace have?

    Synthace has 2 offices.